The Centers for Medicare & Medicaid Services has selected 61 applicants for the Value in Opioid Use Disorder Treatment Demonstration, a four-year Medicare payment model beginning this month for selected health care providers who agree to participate.

Participants will test whether a new care management fee and performance-based incentive payment for OUD treatment services reduces hospitalizations and improves health outcomes for Medicare fee-for-service patients with OUDs, including those dually eligible for Medicaid. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 authorizes $10 million annually in fiscal years 2021-2024 to pay for the treatment services. 

Headline
The Food and Drug Administration March 5 issued a request for information seeking public comments on potential new standards for in-home opioid disposal…
Headline
 The AHA March 3 urged the Health Resources and Services Administration to take immediate action to stop a new Novo Nordisk policy from taking effect…
Headline
The Health Resources and Services Administration Feb. 25 said it will extend the deadline to April 20 to receive comments on its request for information on…
Headline
The U.S. District Court for the District of Hawaii Feb. 23 denied a preliminary injunction requested by AstraZeneca in a case challenging the state’s law…
Headline
The AHA, joined by several other national groups representing 340B hospitals, Feb. 19 urged the Health Resources and Services Administration to extend the…
Headline
The Minnesota Court of Appeals Feb. 17 affirmed a lower court decision in ruling that the state’s 340B contract pharmacy law is not preempted by federal law.…